Amodio et al. reported reversed KRAS inhibitor resistance and an increased cell-death ratio in CC and NSCLC patients where a KRAS inhibitor and anti-EGFR antibody (cetuximab) were applied collectively [73]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.